PURPOSE: The study was done to better understand the biological significance of clusterin co-localization with the exfoliation deposits (XF deposits), and provide insight into a pathogenic mechanism involving activation of the complement system and its pro-inflammatory consequences in patients with exfoliation glaucoma. METHODS: Exfoliation lens deposits were analyzed by high resolution atomic force microscopy imaging and confocal immunofluorescence. Levels of clusterin and vitronectin, as well as of the complement activation products C3a and soluble C5b-9, were assessed via ELISA. RESULTS: Atomic-force microscopy examination of lenses with exfoliation syndrome (XFS) revealed a dense fibrillar network on the anterior, aqueous-bathed surface of the lens, while the epithelial side displayed no discernible structural features at the same resolution. Clusterin colocalized with XF deposits, demonstrating integral association with the fibrils. Levels of activation-derived complement components C3a and soluble C5b-9, as well as the complement inhibitors clusterin and vitronectin, were found significantly elevated (1.7-fold, P < 0.05; 4.1-fold, P < 0.05; 1.8-fold, P < 0.01; and 3.0-fold, P < 0.01, respectively) in aqueous humor from glaucoma patients with XFS compared to non-XFS glaucoma controls. CONCLUSIONS: The data provide compelling evidence for the activation of the complement system in XFS, highlighting the generation of subproducts with potent proinflammatory activity, which are capable of triggering and chronically maintaining levels of subclinical inflammation, suggesting novel targets for therapeutic intervention. The colocalization of clusterin in exfoliation fibrils suggests a failed attempt to prevent tissue accumulation of protein aggregates, as seen in other protein folding disorders, likely due to the abnormal high levels of misfolded proteins overwhelming its chaperone capacity.
PURPOSE: The study was done to better understand the biological significance of clusterin co-localization with the exfoliation deposits (XF deposits), and provide insight into a pathogenic mechanism involving activation of the complement system and its pro-inflammatory consequences in patients with exfoliation glaucoma. METHODS: Exfoliation lens deposits were analyzed by high resolution atomic force microscopy imaging and confocal immunofluorescence. Levels of clusterin and vitronectin, as well as of the complement activation products C3a and soluble C5b-9, were assessed via ELISA. RESULTS: Atomic-force microscopy examination of lenses with exfoliation syndrome (XFS) revealed a dense fibrillar network on the anterior, aqueous-bathed surface of the lens, while the epithelial side displayed no discernible structural features at the same resolution. Clusterin colocalized with XF deposits, demonstrating integral association with the fibrils. Levels of activation-derived complement components C3a and soluble C5b-9, as well as the complement inhibitors clusterin and vitronectin, were found significantly elevated (1.7-fold, P < 0.05; 4.1-fold, P < 0.05; 1.8-fold, P < 0.01; and 3.0-fold, P < 0.01, respectively) in aqueous humor from glaucomapatients with XFS compared to non-XFSglaucoma controls. CONCLUSIONS: The data provide compelling evidence for the activation of the complement system in XFS, highlighting the generation of subproducts with potent proinflammatory activity, which are capable of triggering and chronically maintaining levels of subclinical inflammation, suggesting novel targets for therapeutic intervention. The colocalization of clusterin in exfoliation fibrils suggests a failed attempt to prevent tissue accumulation of protein aggregates, as seen in other protein folding disorders, likely due to the abnormal high levels of misfolded proteins overwhelming its chaperone capacity.
Entities:
Keywords:
complement system; exfoliation syndrome; extracellular chaperones; protein misfolding disorders
Authors: Matthias Zenkel; Friedrich E Kruse; Anselm G Jünemann; Gottfried O H Naumann; Ursula Schlötzer-Schrehardt Journal: Invest Ophthalmol Vis Sci Date: 2006-05 Impact factor: 4.799
Authors: A Rostagno; Y Tomidokoro; T Lashley; D Ng; G Plant; J Holton; B Frangione; T Revesz; J Ghiso Journal: Cell Mol Life Sci Date: 2005-08 Impact factor: 9.261
Authors: S Fossati; J Cam; J Meyerson; E Mezhericher; I A Romero; P O Couraud; B B Weksler; J Ghiso; A Rostagno Journal: FASEB J Date: 2009-09-21 Impact factor: 5.191
Authors: Vadim S Ten; Jun Yao; Veniamin Ratner; Sergey Sosunov; Deborah A Fraser; Marina Botto; Baalasubramanian Sivasankar; B Paul Morgan; Samuel Silverstein; Raymond Stark; Richard Polin; Susan J Vannucci; David Pinsky; Anatoly A Starkov Journal: J Neurosci Date: 2010-02-10 Impact factor: 6.167
Authors: Kathryn P Burdon; Shiwani Sharma; Alex W Hewitt; Amy E McMellon; Jie Jin Wang; David A Mackey; Paul Mitchell; Jamie E Craig Journal: Mol Vis Date: 2008-09-22 Impact factor: 2.367
Authors: Bao J Fan; Louis R Pasquale; Jae H Kang; Hani Levkovitch-Verbin; Jonathan L Haines; Janey L Wiggs Journal: Exp Eye Res Date: 2015-08-10 Impact factor: 3.467
Authors: Pete A Williams; Catherine E Braine; Nicole E Foxworth; Kelly E Cochran; Simon W M John Journal: J Neuroinflammation Date: 2017-04-26 Impact factor: 8.322
Authors: Pete A Williams; James R Tribble; Keating W Pepper; Stephen D Cross; B Paul Morgan; James E Morgan; Simon W M John; Gareth R Howell Journal: Mol Neurodegener Date: 2016-04-06 Impact factor: 14.195
Authors: Mehdi Mirzaei; Veer B Gupta; Joel M Chick; Todd M Greco; Yunqi Wu; Nitin Chitranshi; Roshana Vander Wall; Eugene Hone; Liting Deng; Yogita Dheer; Mojdeh Abbasi; Mahdie Rezaeian; Nady Braidy; Yuyi You; Ghasem Hosseini Salekdeh; Paul A Haynes; Mark P Molloy; Ralph Martins; Ileana M Cristea; Steven P Gygi; Stuart L Graham; Vivek K Gupta Journal: Sci Rep Date: 2017-10-04 Impact factor: 4.379